A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia
Table 2
Percentage of patients with trough BP < 140/85 mm Hg, BP < 130/80 mm Hg, and BP 198 < 140/90 mm Hg using GEE (logistic regression model): FAS and LOCF.
Trough BP
Visit
Switched (n = 289)
Patients
Add-on (n = 90)
Overall (N = 380)
<140/85 mm Hg
Week 6
N′
276
85
362
n (%)
178 (64.5)
54 (63.5)
233 (64.4)
Adjusted %
58.9
58.2
58.7
99% CI
(48.99, 68.12)
(41.22, 73.48)
(49.53, 67.36)
95% CI
(51.38, 66.01)
(45.25, 70.16)
(51.75, 65.37)
Week 12
N′
276
85
362
n (%)
165 (59.8)
56 (65.9)
221 (61.0)
Adjusted %∗
53.4
61.0
54.8
99% CI
(43.40, 63.08)
(44.07, 75.70)
(45.54, 63.78)
95% CI
(45.76, 60.82)
(48.15, 72.56)
(47.75, 61.70)
<130/80 mm Hg
Week 6
N′
276
85
362
n (%)
83 (30.1)
28 (32.9)
111 (30.7)
Adjusted %∗
22.6
24.9
22.9
99% CI
(14.46, 33.44)
(13.09, 42.15)
(14.93, 33.40)
95% CI
(16.15, 30.61)
(15.39, 37.64)
(16.60, 30.67)
Week 12
N′
276
85
362
n (%)
93 (33.7)
34 (40.0)
127 (35.1)
Adjusted %∗
25.9
31.8
27.0
99% CI
(17.01, 37.26)
(18.66, 48.66)
(18.18, 37.99)
95% CI
(18.88, 34.34)
(21.37, 44.45)
(20.06, 35.18)
<140/90 mm Hg
Week 6
N′
276
85
362
n (%)
186 (67.4)
56 (65.9)
243 (67.1)
Adjusted %∗
64.0
63.0
63.8
99% CI
(54.59, 72.41)
(45.37, 77.74)
(55.12, 71.72)
95% CI
(56.89, 70.51)
(49.65, 74.63)
(57.26, 69.93)
Week 12
N′
276
85
362
n (%)
182 (65.9)
58 (68.2)
240 (66.3)
Adjusted %∗
62.2
65.9
62.8
99% CI
(52.51, 71.04)
(48.42, 79.92)
(53.88, 70.96)
95% CI
(54.88, 69.04)
(52.74, 77.00)
(56.06, 69.11)
CI, confidence interval; FAS, full analysis set; GEE, generalized estimated equation; LOCF, last observation carried forward. N' = number of patients with nonmissing values and used as denominator to calculate percentage. The GEE logistic regression model was adjusted for baseline SBP (systolic blood pressure), country, baseline hypertension treatment status, and visit. One patient from the treatment-naïve group was considered only in the overall analysis.
